Effectiveness of estrogen treatment before transcervical resection of adhesions on moderate and severe uterine adhesion patients

Abstract

Intrauterine adhesion (IUA), also known as Asherman’s syndrome, is a common disease for among women. The extent of adhesion and pre-surgery hormone therapy greatly affects the function of uterine cavity. This current study investigates the association of different doses of estrogen before transcervical resection of adhesions (TCRA) surgery and clinical outcome in serious IUA. About 120 newly diagnostic serious IUA patients who underwent TCRA were randomly divided into three study groups: Estradiol valerate (progynova) 3 or 9 mg per diet before surgery and the control group. Follow-up hysteroscopy checkups were taken in 1- and 3-month post-operation. The effective power of 9 mg group was significantly higher than other groups. The 9 mg group achieved the best menstrual recovery rate in all study groups compared with the other two groups in 6 months post-operatively (p < 0.05). Our results confirmed estradiol valerateas an alternative effective drug for the prevention of IUAs before and after hysteroscopic surgery.

Chinese abstract

宫腔粘连 (Intrauterine adhesion, IUA) , 又称Asherman’s综合征, 是一种女性常见疾病。粘连程度和术前的激素治疗极大地影响宫腔功能。本研究探讨严重IUA患者行宫腔粘连切除术 (transcervical resection of adhesions, TCRA) 前应用不同剂量的雌激素与临床结局的关系。120例新诊断为严重IUA需行TCRA手术的患者随机分为3组：术前每天服戊酸雌二醇 (补佳乐) 3或9mg, 以及对照组。术后1个月和3个月进行宫腔镜检查的随访。9mg组的疗效显著高于其他组。与其他两组相比, 术后6个月9mg组的月经恢复率最高 (p < 0.05) 。我们的结果证实, 宫腔镜检查手术前后应用戊酸雌二醇片预防IUA是一种可选择的有效药物。

Keywords:

• Estradiol valerate
• hysteroscopy
• intrauterine adhesions

Declaration of interest

All authors declared no interest of conflict. This study is supported by Zhengzhou City Programs for Science and Technology (No. 20150177). All participants sign the consent form to publish individual data.